February 11, 2025
Revolo to Present at the 2025 AAAAI / WAO Joint Congress
GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom, Feb. 10, 2025 (GLOBE NEWSWIRE) — Revolo Biotherapeutics Limited (“Revolo”) today announced that it…
Pharmaceuticals, Biotechnology and Life Sciences
GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom, Feb. 10, 2025 (GLOBE NEWSWIRE) — Revolo Biotherapeutics Limited (“Revolo”) today announced that it…
Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31,…
Trading Under New Ticker of “EXOZ” Expected to Begin February 12, 2025Monrovia, CA, Feb. 10, 2025 (GLOBE NEWSWIRE) — Today,…
FDA RMAT designation follows positive proof-of-concept U.S. clinical data from the NXC-201 NEXICART-2 clinical trial in relapsed/refractory AL AmyloidosisRMAT designation…
WALTHAM, Mass. and BOULDER, Colo., Feb. 10, 2025 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on…
SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based…
Data presented at the 2025 Crohn’s and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model…
RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2025 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will…
EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen…
At three years of EYLEA HD treatment, the vast majority of patients maintained visual and anatomic improvements while achieving extended…